Attention Deficit Drugs Part 3.docx

\#\#\# Slide 11 - Non-stimulants (Atomoxetine) 1\. \*\*Which of the following non-stimulant medications is approved for the treatment of ADHD?\*\* \- A) Fluoxetine \- B) Atomoxetine \- C) Venlafaxine \- D) Diazepam \*\*Answer\*\*: B) Atomoxetine 2\. \*\*What is a common adverse effect of atom...

\#\#\# Slide 11 - Non-stimulants (Atomoxetine) 1\. \*\*Which of the following non-stimulant medications is approved for the treatment of ADHD?\*\* \- A) Fluoxetine \- B) Atomoxetine \- C) Venlafaxine \- D) Diazepam \*\*Answer\*\*: B) Atomoxetine 2\. \*\*What is a common adverse effect of atomoxetine?\*\* \- A) Hepatotoxicity \- B) Weight gain \- C) Tachycardia \- D) Seizures \*\*Answer\*\*: A) Hepatotoxicity 3\. \*\*How long does it typically take for atomoxetine to show its therapeutic effects?\*\* \- A) 1 week \- B) 2 days \- C) 4-6 weeks \- D) 3 months \*\*Answer\*\*: C) 4-6 weeks \#\#\# Slide 12 - Non-Stimulant Therapy 4\. \*\*Which non-stimulant medication is a norepinephrine reuptake inhibitor used for ADHD?\*\* \- A) Clonidine \- B) Guanfacine \- C) Atomoxetine \- D) Methylphenidate \*\*Answer\*\*: C) Atomoxetine 5\. \*\*Why might atomoxetine be preferred over stimulants in some ADHD patients?\*\* \- A) Faster onset of action \- B) Lower risk of abuse and dependence \- C) Better efficacy in all age groups \- D) No monitoring required \*\*Answer\*\*: B) Lower risk of abuse and dependence 6\. \*\*What monitoring is recommended with atomoxetine use?\*\* \- A) Renal function \- B) Cardiac function \- C) Liver function \- D) Pulmonary function \*\*Answer\*\*: C) Liver function \#\#\# Slide 13 - Alpha-2 Agonists 7\. \*\*Clonidine and guanfacine are alpha-2 agonists primarily used to treat which symptoms of ADHD?\*\* \- A) Hyperactivity and impulsivity \- B) Inattention and mood changes \- C) Cognitive impairment \- D) Sleep disturbances \*\*Answer\*\*: A) Hyperactivity and impulsivity 8\. \*\*What is a common side effect associated with alpha-2 agonists like clonidine?\*\* \- A) Weight gain \- B) Hypertension \- C) Sedation \- D) Hyperactivity \*\*Answer\*\*: C) Sedation 9\. \*\*Why are alpha-2 agonists like guanfacine and clonidine often used in combination with stimulants?\*\* \- A) To enhance the effect of inattention symptoms \- B) To reduce hyperactivity symptoms and provide sedative benefits \- C) To increase alertness \- D) To minimize side effects of the stimulant \*\*Answer\*\*: B) To reduce hyperactivity symptoms and provide sedative benefits \#\#\# Slide 14 - Bupropion 10\. \*\*Bupropion, used off-label for ADHD, primarily affects which neurotransmitter system?\*\* \- A) Dopamine and norepinephrine \- B) Serotonin and acetylcholine \- C) GABA and glutamate \- D) Histamine and serotonin \*\*Answer\*\*: A) Dopamine and norepinephrine 11\. \*\*What is a significant contraindication for bupropion use?\*\* \- A) Seizure disorders \- B) ADHD combined type \- C) Weight gain \- D) Sleep disturbances \*\*Answer\*\*: A) Seizure disorders 12\. \*\*Which of the following side effects is more commonly associated with bupropion in ADHD treatment?\*\* \- A) Sleep improvement \- B) Insomnia \- C) Increased appetite \- D) Sedation \*\*Answer\*\*: B) Insomnia \#\#\# Slide 15 - Viloxazine (Qelbree) 13\. \*\*What is the mechanism of action of viloxazine, a new non-stimulant ADHD medication?\*\* \- A) Norepinephrine reuptake inhibition \- B) Dopamine reuptake inhibition \- C) GABA agonist \- D) Serotonin receptor antagonist \*\*Answer\*\*: A) Norepinephrine reuptake inhibition 14\. \*\*For which age group is viloxazine approved in ADHD treatment?\*\* \- A) 2 years and older \- B) 6 years and older \- C) 10 years and older \- D) 12 years and older \*\*Answer\*\*: B) 6 years and older 15\. \*\*What is a potential adverse effect of viloxazine?\*\* \- A) Increased blood pressure and heart rate \- B) Weight gain \- C) Hypotension \- D) Hyperactivity \*\*Answer\*\*: A) Increased blood pressure and heart rate